Özdemir, ElifCoşkun, NazımAltun, Gülay DurmuşDemir, HakanÖzdemir, SemraÇağlıyan, FeyzaÖzkan, Elgin2025-05-292025-05-2920242149-6447https://doi.org/10.4274/nts.galenos.2024.0008https://hdl.handle.net/20.500.12428/29974Amyloidosis is a systemic disorder characterized by the extracellular deposition of amyloid fibrils in various tissues, with the potential for cardiac involvement. Cardiac amyloidosis, a relatively uncommon and frequently underdiagnosed etiology of heart failure, can manifest due to the infiltration of several amyloid types into the myocardium. The definitive diagnosis typically involves an endomyocardial biopsy. Utilizing scintigraphic imaging with Technetium-99m (Tc-99m) labeled bisphosphonates can aid in the early identification of cardiac involvement and differentiate between different forms of cardiac amyloidosis. This guideline aims to support nuclear medicine practitioners in advising, performing imaging procedures, documenting findings, and interpreting results from scintigraphy involving Tc-99mlabeled bone radiopharmaceuticals for the assessment of transthyretin cardiac amyloidosis. © 2024 Galenos Publishing House. All rights reserved.trinfo:eu-repo/semantics/openAccessCardiac amyloidosisscintigraphySPECTSPECT/CTReview1019010310.4274/nts.galenos.2024.00082-s2.0-85190998773Q4